Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Cosyntropin for treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (CROSBI ID 94256)

Prilog u časopisu | Pismo uredniku

Sepčić, Juraj ; Radolović, Lorena ; Weiner-Črnja, Mima ; Rudež, Josip Cosyntropin for treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) // Acta Facultatis Medicae Fluminensis, 23 (1998), 2; 85-87-x

Podaci o odgovornosti

Sepčić, Juraj ; Radolović, Lorena ; Weiner-Črnja, Mima ; Rudež, Josip

engleski

Cosyntropin for treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

CIDP is manifested by inflammatory myelin lesion primarily in the roots and proyimal segments of peripheral nerves. The cause is not known. Immunological studies suggest that it is, a least partially, a T-cell-mediated disorder. The disease is eighter chronic or intermittent with exacebations. CIDP is diagnosed by clinical, electrophysiological, and histopathological findings, as well as cerebrospinal fluid (CSF) analysis. Immunomodulating steroids, plasma-exchange, or intravenous immunoglobulins are considered to be effective treatments. The patient presented in this letter is a case of the hypertrophic variant od CIDP, combined with CNS demyelinization. The administration of cosyntropin during relapses has always resulted in excellent remissions. We conclude that cosyntropin his its place in the CIDP treatment. The results of its application correlate with those obtained with much more expensive medications and/or procedures.

CIDP; Cosyntropin; Therapy

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

23 (2)

1998.

85-87-x

objavljeno

0065-1206

Povezanost rada

Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita

Indeksiranost